Sales Success with Lyprinol

1
Sales Success with Lyprinol PCSO-524TM
Lipid-ComplexTony Jacobs and Simon Barryon
Behalf of Enliten Healthcare Ltd
The Stabilised and Patented NZ Green Lipped
Mussel CO2 Supercritical non-polar lipid extract
oil
2
Safe Treatment with Lyprinol for

• Ostheo-Arthritis
• Rheumatoid Arthritis (also in conjunction with
  base medication)
• Asthma and Bronchial Constriction
• Chronic Inflammation due to
• Ageing
• Sports
• Natural Anti-Inflammatory
• No Side Effects
• Complimentary to existing treatments

3
Contents of Lyprinol

• PCSO-524TM Lipid-Complex 50 mg
• (Oil from NZ Green Lipped Mussels)
• Pharma Olive oil 100 mg
• Vitamin E (d-a-tocopherol) 0.225 mg
• Soft Gel Capsule (Bovine Gelatine)

• Contains only the Lipids Active Substance
• (5 of the dried mussel powder)
• 105 to 1 DER concentration

4
Lyprinol driven by Studies

• Over 30 Studies to date
• 4 studies about to be published in Peer Journals
• 4 studies are still on going
• Annual Sales Growth of 30

5
Works by Competive Inhibition of Cox and Lox
6
Jacek Szechinski, 2011

• Comparison of the effectiveness of Lyprinol
  versus Fish Oil, same dose of 200mg per day
• 50 Patients, double blind
• Duration 3 months
• No side effects for
• Lyprinol
• Pain reduction starting
• after 4 weeks

7
Recently Completed Studies

• New Zealand Lyprinol Juvenile Asthma Study.
   Single center, randomized, double-blind,
  placebo-controlled comparative study of 85
  children between 6 and 13 years. Significant
  Improvement 
• Endurance Sport Protocol, Cologne, Germany.  To
  be published in the online British Sports
  Medicine Journal in MayDemonstrated Pain Relief
• Osteoarthritis Study, Poland.  Published in the
  Special Issue 'Marine Compounds and Inflammation'
  of the peer-reviewed scientific Marine Drugs
  journal
• Demonstrated reduced arthritis-related pain by
  89, with 91 of participants reporting an
  improved quality of life.
• Exercise Induced Bronchial Constriction (EIBC),
  Indiana, USA.Study completed and been accepted
  for publication in the Medical Respiratory
  Journal.Demonstrated significant reduction of
  EIBC symptons. Reduced use of inhalers by 83.
  Improved lung function of 59 after just 3 weeks.

8
Studies still in Progress

• ADHD/Behavioural Study, Swinburne University,
  Melbourne, Australia.  An 8 week phase II/III
  double-blind, placebo-controlled, cross-over
  study will test Lyprinol with placebo (capsules)
  in 150 children/adolescents with ADHD symptoms,
  aged between 7 and 13 years old.  Expected to be
  competed in October
• Elite Sports Muscle Soreness Trial, Indiana,
  USA.Being conducted by leading Physiology
  Faculty in US for élite Sports competition.
   Expected to be completed in November 
• Effects Of PCSO-524 On Arterial Plaque
  Formation, Charité Medical University, Berlin,
  Germany.  This study uses the latest laser
  measurement technology, ellipsometry, to identify
  and classify the inhibitory effects of compounds,
  in this case PCSO-524 relative to arterial
  plaque formation.   Expected to be completed in
  July  
• Endothelial Functionality and synergy with
  polyphenols, NIH BethsedaA five stream and
  placebo controlled study funded by the NIH. Due
  to be completed by December

9
Sales

• Australia sells approximately 7,600 pack sales of
  Lyprinol per month
• We have a much larger potential market here in
  the UK. The UK has built from only word-of-mouth
  and recommedation to around 2,000 packs per month
  through direct sales. We expect to see signifcant
  increase with the latest research PR activity,
  and the right partners!